Biography

Education:

1990.9-1995.7   Bachelor  Hubei Medical University, Clinical Medicine Major

1998.9-2001.7   Master   Wuhan University, Surgery Major

2002.9-2006.7   ph.D.    Wuhan University, Surgery Major

Professional Appointments:

1995.8-2003.11 Department of General Surgery, Zhongnan Hospital of Wuhan University. Resident surgeon

2003.12-2006.11 Department of General Surgery, Zhongnan Hospital of Wuhan University. Surgeon-in-charge

2006.12-2011.11 Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University. Associate chief surgeon

2008.4-2008.6   Claude Huriez Hospital of Lille University, France. Visiting scholar

2008.9-2008.11 Fukushima Medical University Hospital, Japan. Visiting scholar

2008.11-2009.11 Brabois Hospital of Nancy University, France.  Post-doctor

2011.12-2019.11 Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University. Chief surgeon

2019.12-Present Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University. Chief surgeon, Professor

Honors

2020  Medal winner of the second National Innovation Competition Award

2021  National May Day Labor Medal winner

2021  The ninth Wuhan University "Zhu Yubi Medical Award" winner

2022  The 10th National Young and Middle-aged Experts with Outstanding Contributions to Health

Professional Membership and Offices:

Vice-chairman，Department of  Surgery, Zhongnan Hospital of Wuhan University

Director, Clinical Medicine Research Center for Minimally Invasive Procedure of Hepatobiliary & Pancreatic Diseases of Hubei Province

Member, International Hepatobiliary and Pancreatic Association(IHPBA)

Member, Hepatology Group, Surgery Society of Chinese Medical Association

Deputy director member, General Surgery Branch of Hubei Medical Association

Director member, Endoscopy Surgery Branch of Wuhan Medical Association

Research

Professor Yuan Yufeng and his team focus on the pathogenesis of primary liver cancer and metabolic liver disease, as well as the research of the early diagnosis and minimally invasive treatment of hepatobiliary and Pancreatic tumors. He has led 13 national and provincial level research projects, and published 92 SCI papers. Representative academic achievements are as follows:
1. Study on the application of ICG fluorescence navigation in hepatobiliary surgery, including the concentration, dose, and time of ICG use, ICG staining methods for different parts of liver resection.

2.Study on the molecular mechanisms of liver cancer,especially the effects of lipid metabolism, glucose metabolism, and other factors on the occurrence and development of liver cancer.
3. Study the capture methods of circulating biomarkers and their application in precise diagnosis and treatment of liver cancer.

4.Study on the pathogenesis of non-alcoholic fatty liver disease and the application of bariatric surgery in metabolic diseases.

Representative  Publications

1. Wu TG^#，Chen X^#, Xu KQ, Dai CX, Li XM, Zhang YWQ, Li JH, Gao M, Liu YY, Liu FS, Zhang XT, Wang BC, Xia P, Li Z, Ma WJ^*, Yuan YF^*.  LIM domain only 7 negatively controls non-alcoholic steatohepatitis in the setting of hyperlipidaemia. Hepatology. 2023 Sep; doi: 10.1097/HEP.0000000000000585.

2. Yang Q^#, Chen X^#, Zhang Y^#, Hu S, Hu F, Huang Y, Ma T, Hu H, Tian H, Tian S, Ji YX, She ZG, Zhang P, Zhang XJ, Hu Y, Yang H^*, Yuan YF^*, Li HL^*. The E3 ubiquitin ligase Rnf5 ameliorates nonalcoholic steatohepatitis via ubiquitin-mediated degradation of Hrd1. Hepatology. 2021 Dec;74(6):3018-3036.

3. Xia P^#, Yuan HT^#, Tian M^#, Zhong TY, Hou R, Xu XL, Ma JB, Wang HF, Li ZF, Huang DF, Qu CM, Dai LY, Xu CC, Yang CB, Jiang HB, He YQ, Felix Rückert, Li ZJ*, Yuan YF^*, Wang JG*. Surface-Engineered Extracellular Vesicles with CDH17 Nanobodies to Efficiently Deliver Imaging Probes and Chemo-Photothermal Drugs for Gastric Cancer Theragnostic. Advanced Functional Material. 2023 Feb; 33 (7).

4. Xia P^#, Zhang H^#, Lu HF^#, Xu KQ, Jiang X, Jiang YK, GY XD, Chen Z, Liu J, Chen X, Ma WJ, Zhang ZL^*, Yuan YF^*. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression. Cancer communication. 2023 Mar; 43(3): 338-364.

Li JH^#, Xu K^#, Guo DL^#, Liao B, Zhu Q, Wang HT, Jiang YQ, Wu DD, Xia XG, Jiang P, Tang SL, Yang ZY, He YM, Zhang ZL^*, He Y^*, Yuan YF^*. Clinical prospective study of Gallium 68 (68Ga)-labeled fibroblast‑activation protein inhibitor PET/CT in the diagnosis of biliary tract carcinoma. Eur J Nucl Med Mol Imaging. 2023 Jun; 50(7):2152-2166.